UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Annals of oncology, 2016-07, Vol.27 (7), p.1241-1248

2016

Volltextzugriff (PDF)

Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4+ T cell responses

Clinical and experimental allergy, 2011-02, Vol.41 (2), p.192-203

2011

Volltextzugriff (PDF)

Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs

Antimicrobial Agents and Chemotherapy, 1997-12, Vol.41 (12), p.2699-2704

1997

Volltextzugriff (PDF)

Recognition of Ii-Key/MHC class II epitope hybrids derived from proinsulin and GAD peptides by T cells in type 1 diabetes

Hormone and metabolic research, 2011-06, Vol.43 (7), p.483-488

2011

Volltextzugriff (PDF)

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide

Vaccine, 2000-06, Vol.18 (24), p.2693-2697

2000

Volltextzugriff (PDF)

POD-04.04: Phase I Clinical Study of the Novel LI-Key/HER-2(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer

Urology (Ridgewood, N.J.), 2009, Vol.74 (4), p.S11-S11

2009

Volltextzugriff (PDF)

Sensitization of multidrug-resistant human leukemia cells with MDR1-targeted antisense and inhibition of drug-mediated MDR1 induction

Leukemia, 1997-07, Vol.11 (7), p.950-957

1997

Volltextzugriff (PDF)

MHC Class II Allosteric Site Drugs: New Immunotherapeutics for Malignant, Infectious and Autoimmune Diseases

Scandinavian journal of immunology, 2001-07, Vol.54 (1‐2), p.39-44

2001

Volltextzugriff (PDF)

Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

Cancer Immunology, Immunotherapy, 2007-05, Vol.56 (5), p.601-613

2007

Volltextzugriff (PDF)

Single Cell Assessment of Allergen-Specific T Cell Responses with MHC Class II Peptide Tetramers: Methodological Aspects

International archives of allergy and immunology, 2008-01, Vol.146 (2), p.99-112

2008

Volltextzugriff (PDF)

Inhibition of Tumorigenesis by a Cytosine-DNA, Methyltransferase, Antisense Oligodeoxynucleotide

Proceedings of the National Academy of Sciences - PNAS, 1997-01, Vol.94 (2), p.684-689

1997

Volltextzugriff (PDF)

Interim Analysis of a Randomized Phase II Study of the Novel Ii-Key Hybrid HER2/ Neu Peptide (AE37) Vaccine To Prevent Breast Cancer Recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (24_Supplement), p.3183-3183

2009

Volltextzugriff (PDF)

Results from the first phase I clinical study of the novel Ii-Key/HER2/neu(776–790) hybrid peptide vaccine in patients with prostate cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3011-3011

2009

Volltextzugriff (PDF)

Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.3016-3016

2008

Volltextzugriff (PDF)

Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/ neu peptide (AE37)

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.3134

2009

Volltextzugriff (PDF)

Relationship Between O6-Alkylguanine-DNA Alkyltransferase Activity and N-Methyl-N'-Nitro-N-Nitrosoguanidine-Induced Mutation, Transformation, and Cytotoxicity in C3H/10T1/2 Cells Expressing Exogenous Alkyltransferase Genes

Proceedings of the National Academy of Sciences - PNAS, 1992-12, Vol.89 (23), p.11199-11203

1992

Volltextzugriff (PDF)

Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein

Human gene therapy, 2005-02, Vol.16 (2), p.187-199

2005

Volltextzugriff (PDF)

Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease

Frontiers in bioscience, 2006-01, Vol.11 (1), p.46

2006

Volltextzugriff (PDF)

Linkage of Ii-Key segment to gp100(46–58) epitope enhances the production of epitope-specific antibodies

Vaccine, 2005-03, Vol.23 (17), p.2336-2338

2005

Volltextzugriff (PDF)

Early results of a phase I clinical trial of an Ii-Key/Her2/ neu MHC class II peptide-based vaccine in breast cancer patients

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.2532-2532

2006

Volltextzugriff (PDF)

Immunological monitoring of in vitro and in vivo immune responses to the Ii-Key/HER2/neu MHC class II peptide vaccine in a phase I clinical trial in breast cancer patients

The Journal of surgical research, 2006-02, Vol.130 (2), p.217-218

2006

Volltextzugriff (PDF)

Modulation of mouse fibroblast adipocyte differentiation by X-rays and TPA

Cancer letters, 1990-10, Vol.54 (1), p.9-15

1990

Volltextzugriff (PDF)

Inhibition of X-ray-induced exencephaly by protease inhibitors

Radiation research, 1990-07, Vol.123 (1), p.108

1990

Volltextzugriff (PDF)

Genetic modulation of tumor antigen presentation

Trends in Biotechnology, 2000-04, Vol.18 (4), p.167-172

2000

Volltextzugriff (PDF)

Interorgan shift of nitrosamine metabolism by dietary ethanol

Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement, 1987, Vol.11, p.53

1987

Volltextzugriff (PDF)

1 – 25 von 159

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(134)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(42)
Animals
(40)
Life Sciences & Biomedicine
(35)
Humans
(30)
Biological And Medical Sciences
(27)
Mice
(22)
Medical Sciences
(20)
Male
(17)
Tumors
(16)
Female
(14)
Histocompatibility Antigens Class Ii - Immunology
(13)
Oncology
(11)
Immunology
(10)
Rats
(10)
Antigens, Differentiation, B-Lymphocyte - Immunology
(9)
Carcinogenesis, Carcinogens And Anticarcinogens
(9)
Cd4-Positive T-Lymphocytes - Immunology
(9)
Chemical Agents
(9)
Dna - Metabolism
(9)
Fundamental And Applied Biological Sciences. Psychology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Distinct characteristics of seasonal (Bet v 1) vs. perennial (Der p 1/Der p 2) allergen-specific CD4+ T cell responses

Inhibition of the multiple antibiotic resistance (mar) operon in Escherichia coli by antisense DNA analogs

Recognition of Ii-Key/MHC class II epitope hybrids derived from proinsulin and GAD peptides by T cells in type 1 diabetes

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide

POD-04.04: Phase I Clinical Study of the Novel LI-Key/HER-2(776-790) Hybrid Peptide Vaccine in Patients with Prostate Cancer

Sensitization of multidrug-resistant human leukemia cells with MDR1-targeted antisense and inhibition of drug-mediated MDR1 induction

MHC Class II Allosteric Site Drugs: New Immunotherapeutics for Malignant, Infectious and Autoimmune Diseases

Ii-Key/HER-2/neu(776-90) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

Single Cell Assessment of Allergen-Specific T Cell Responses with MHC Class II Peptide Tetramers: Methodological Aspects

Inhibition of Tumorigenesis by a Cytosine-DNA, Methyltransferase, Antisense Oligodeoxynucleotide

Interim Analysis of a Randomized Phase II Study of the Novel Ii-Key Hybrid HER2/ Neu Peptide (AE37) Vaccine To Prevent Breast Cancer Recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05

Results from the first phase I clinical study of the novel Ii-Key/HER2/neu(776–790) hybrid peptide vaccine in patients with prostate cancer

Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03

Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/ neu peptide (AE37)

Relationship Between O6-Alkylguanine-DNA Alkyltransferase Activity and N-Methyl-N'-Nitro-N-Nitrosoguanidine-Induced Mutation, Transformation, and Cytotoxicity in C3H/10T1/2 Cells Expressing Exogenous Alkyltransferase Genes

Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein

Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease

Linkage of Ii-Key segment to gp100(46–58) epitope enhances the production of epitope-specific antibodies

Early results of a phase I clinical trial of an Ii-Key/Her2/ neu MHC class II peptide-based vaccine in breast cancer patients

Immunological monitoring of in vitro and in vivo immune responses to the Ii-Key/HER2/neu MHC class II peptide vaccine in a phase I clinical trial in breast cancer patients

Modulation of mouse fibroblast adipocyte differentiation by X-rays and TPA

Inhibition of X-ray-induced exencephaly by protease inhibitors

Genetic modulation of tumor antigen presentation

Interorgan shift of nitrosamine metabolism by dietary ethanol

Suchergebnisse filtern